Clinical Trial Update: Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cetuximab plus dalpicilib in HPV-negative, PD-1 resistant recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Dalpicilib

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN